Recombinant Human Acid Sphingomyelinase as an Adjuvant to Sorafenib Treatment of Experimental Liver Cancer

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Savić, Radoslav ^a   He, Xingxuan ^a   Fiel, Isabel ^a   Schuchman, Edward H ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; RECOMBINANT HUMAN ACID SPHINGOMYELINASE; SORAFENIB; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; LIVER CANCER; LIVER CELL CARCINOMA; LIVER PARENCHYMA; MOUSE; NONHUMAN; TUMOR NECROSIS; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOTHERAPY, ADJUVANT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, SCID; NEOPLASM PROTEINS; NIACINAMIDE; PHENYLUREA COMPOUNDS; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; SPHINGOLIPIDS; SPHINGOMYELIN PHOSPHODIESTERASE; SUBCUTANEOUS TISSUE; SURVIVAL ANALYSIS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84878418606     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065620     Document Type: Article

References (59)

1. Thomas MB, Abbruzzese JL, (2005) Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol 23: 8093-8108.
2. Whittaker S, Marais R, Zhu AX, (2010) The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 29: 4989-5005.
3. FDA website. Available: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm109030.htm. Accessed 2013 May 3.
4. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, et al. (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5: 835-844.
5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390.
6. Zhu AX, (2010) Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma. Expert Opin Investig Drugs 19: 663-672.
7. Schuchman EH, (2009) The pathogenesis and treatment of acid sphingomyelinase-deficient Niemann-Pick disease. Int J Clin Pharmacol Ther 47Suppl 1: S48-57.
8. FDA website. Available: http://www.fda.gov/ohrms/dockets/dailys/04/June04/060304/84n-0102-lst0101-01.pdf. Accessed 2013 May 3.
9. Hannun YA, Obeid LM, (2008) Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 9: 139-150.
10. Oskouian B, Saba JD, (2010) Cancer treatment strategies targeting sphingolipid metabolism. Adv Exp Med Biol 688: 185-205.
11. Ponnusamy S, Meyers-Needham M, Senkal CE, Saddoughi SA, Sentelle D, et al. (2010) Sphingolipids and cancer: ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance. Future Oncol 6: 1603-1624.
12. Tagaram HR, Divittore NA, Barth BM, Kaiser JM, Avella D, et al. (2011) Nanoliposomal ceramide prevents in vivo growth of hepatocellular carcinoma. Gut 60: 695-701.
13. Draper JM, Xia Z, Smith RA, Zhuang Y, Wang W, et al. (2011) Discovery and Evaluation of Inhibitors of Human Ceramidase. Mol Cancer Ther 10: 2052-2061.
14. Smith EL, Schuchman EH, (2008) Acid sphingomyelinase overexpression enhances the antineoplastic effects of irradiation in vitro and in vivo. Mol Ther 16: 1565-1571.
15. NCI website. Available: http://dtp.nci.nih.gov/docs/misc/common_files/cell_list.html. Accessed 2013 May 3.
16. Smith EL (2008) Acid Sphingomyelinase Enhances the Anti-Neoplastic Effects of Irradiation In Vitro and In Vivo. New York: Mount Sinai School of Medicine of NYU.
17. Mas VR, Maluf DG, Archer KJ, Yanek K, Kong X, et al. (2009) Genes involved in viral carcinogenesis and tumor initiation in hepatitis C virus-induced hepatocellular carcinoma. Mol Med 15: 85-94.
18. Chen X, Cheung ST, So S, Fan ST, Barry C, et al. (2002) Gene expression patterns in human liver cancers. Mol Biol Cell 13: 1929-1939.
19. Wurmbach E, Chen YB, Khitrov G, Zhang W, Roayaie S, et al. (2007) Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 45: 938-947.
20. Roessler S, Jia HL, Budhu A, Forgues M, Ye QH, et al. (2010) A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res 70: 10202-10212.
21. Gentschev I, Muller M, Adelfinger M, Weibel S, Grummt F, et al. (2011) Efficient colonization and therapy of human hepatocellular carcinoma (HCC) using the oncolytic vaccinia virus strain GLV-1h68. PLoS One 6: e22069.
22. Lee YH, Judge AD, Seo D, Kitade M, Gomez-Quiroz LE, et al. (2011) Molecular targeting of CSN5 in human hepatocellular carcinoma: a mechanism of therapeutic response. Oncogene 30: 4175-4184.
23. Hikita H, Takehara T, Shimizu S, Kodama T, Shigekawa M, et al. (2010) The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib. Hepatology 52: 1310-1321.
24. NNPDF website. Available: http://www.nnpdf.org/documents/niemannpickposterICIEM09FINAL_000.pdf. Accessed 2013 May 3.
25. Yang J, Liu A, Dougherty C, Chen X, Guzman R, et al. (2000) Beware of contaminating mouse cells in human xenografts from nude mice. Anticancer Res 20: 1635-1639.
26. Waxman S, Wurmbach E, (2007) De-regulation of common housekeeping genes in hepatocellular carcinoma. BMC Genomics 8: 243.
27. Hakomori S, (1973) Glycolipids of tumor cell membrane. Adv Cancer Res 18: 265-315.
28. Barth BM, Cabot MC, Kester M, (2011) Ceramide-Based Therapeutics for the Treatment of Cancer. Anticancer Agents Med Chem 11: 911-919.
29. Kolesnick R, (2002) The therapeutic potential of modulating the ceramide/sphingomyelin pathway. J Clin Invest 110: 3-8.
30. Canals D, Perry DM, Jenkins RW, Hannun YA, (2011) Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases. Br J Pharmacol 163: 694-712.
31. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, et al. (2003) Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300: 1155-1159.
32. Venook AP, Papandreou C, Furuse J, de Guevara LL, (2010) The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 15Suppl 4: 5-13.
33. Mari M, Fernandez-Checa JC, (2007) Sphingolipid signalling and liver diseases. Liver Int 27: 440-450.
34. Muro S, Schuchman EH, Muzykantov VR, (2006) Lysosomal enzyme delivery by ICAM-1-targeted nanocarriers bypassing glycosylation- and clathrin-dependent endocytosis. Mol Ther 13: 135-141.
35. Bao M, Chen Z, Xu Y, Zhao Y, Zha R, et al. (2011) Sphingosine kinase 1 promotes tumour cell migration and invasion via the S1P/EDG1 axis in hepatocellular carcinoma. Liver Int 32: 331-338.
36. He X, Miranda SR, Xiong X, Dagan A, Gatt S, et al. (1999) Characterization of human acid sphingomyelinase purified from the media of overexpressing Chinese hamster ovary cells. Biochim Biophys Acta 1432: 251-264.
37. Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L, et al. (2011) MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology 140: 1618-1628.
38. Sato S, Sato Y, Hatakeyama K, Marutsuka K, Yamashita A, et al. (2011) Quantitative analysis of vessels with smooth muscle layer in astrocytic tumors: correlation with histological grade and prognostic significance. Histol Histopathol 26: 497-504.
39. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, et al. (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099-7109.
40. Beljanski V, Lewis CS, Smith CD, (2011) Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts. Cancer Biol Ther 11: 524-534.
41. Taghian A, Budach W, Zietman A, Freeman J, Gioioso D, et al. (1993) Quantitative comparison between the transplantability of human and murine tumors into the subcutaneous tissue of NCr/Sed-nu/nu nude and severe combined immunodeficient mice. Cancer Res 53: 5012-5017.
42. Zhang XS, Brondyk W, Lydon JT, Thurberg BL, Piepenhagen PA, (2011) Biotherapeutic target or sink: analysis of the macrophage mannose receptor tissue distribution in murine models of lysosomal storage diseases. J Inherit Metab Dis 34: 795-809.
43. Osawa Y, Suetsugu A, Matsushima-Nishiwaki R, Yasuda I, Saibara T, et al. (2013) Liver acid sphingomyelinase inhibits growth of metastatic colon cancer. J Clin Invest.
44. Savic R, Schuchman EH, (2013) Use of acid sphingomyelinase for cancer therapy. Adv Cancer Res 117: 91-115.
45. MacDonald RG, Pfeffer SR, Coussens L, Tepper MA, Brocklebank CM, et al. (1988) A single receptor binds both insulin-like growth factor II and mannose-6-phosphate. Science 239: 1134-1137.
46. Dhami R, Schuchman EH, (2004) Mannose 6-phosphate receptor-mediated uptake is defective in acid sphingomyelinase-deficient macrophages: implications for Niemann-Pick disease enzyme replacement therapy. J Biol Chem 279: 1526-1532.
47. Garnacho C, Dhami R, Simone E, Dziubla T, Leferovich J, et al. (2008) Delivery of acid sphingomyelinase in normal and niemann-pick disease mice using intercellular adhesion molecule-1-targeted polymer nanocarriers. J Pharmacol Exp Ther 325: 400-408.
48. Killian JK, Nolan CM, Wylie AA, Li T, Vu TH, et al. (2001) Divergent evolution in M6P/IGF2R imprinting from the Jurassic to the Quaternary. Hum Mol Genet 10: 1721-1728.
49. Puxbaum V, Nimmerfall E, Bauerl C, Taub N, Blaas PM, et al. (2012) M6P/IGF2R modulates the invasiveness of liver cells via its capacity to bind mannose 6-phosphate residues. J Hepatol 57: 337-343.
50. Braulke T, (1999) Type-2 IGF receptor: a multi-ligand binding protein. Horm Metab Res 31: 242-246.
51. De Souza AT, Hankins GR, Washington MK, Orton TC, Jirtle RL, (1995) M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nat Genet 11: 447-449.
52. Takahashi K, Donovan MJ, Rogers RA, Ezekowitz RA, (1998) Distribution of murine mannose receptor expression from early embryogenesis through to adulthood. Cell Tissue Res 292: 311-323.
53. Liu K, He X, Lei XZ, Zhao LS, Tang H, et al. (2003) Pathomorphological study on location and distribution of Kupffer cells in hepatocellular carcinoma. World J Gastroenterol 9: 1946-1949.
54. Imai Y, Murakami T, Yoshida S, Nishikawa M, Ohsawa M, et al. (2000) Superparamagnetic iron oxide-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading. Hepatology 32: 205-212.
55. Tanaka M, Nakashima O, Wada Y, Kage M, Kojiro M, (1996) Pathomorphological study of Kupffer cells in hepatocellular carcinoma and hyperplastic nodular lesions in the liver. Hepatology 24: 807-812.
56. Cheng Z, Al Zaki A, Hui JZ, Muzykantov VR, Tsourkas A, (2012) Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science 338: 903-910.
57. Savic R, Eisenberg A, Maysinger D, (2006) Block copolymer micelles as delivery vehicles of hydrophobic drugs: micelle-cell interactions. J Drug Target 14: 343-355.
58. He X, Dagan A, Gatt S, Schuchman EH, (2005) Simultaneous quantitative analysis of ceramide and sphingosine in mouse blood by naphthalene-2,3-dicarboxyaldehyde derivatization after hydrolysis with ceramidase. Anal Biochem 340: 113-122.
59. He X, Chen F, Dagan A, Gatt S, Schuchman EH, (2003) A fluorescence-based, high-performance liquid chromatographic assay to determine acid sphingomyelinase activity and diagnose types A and B Niemann-Pick disease. Anal Biochem 314: 116-120.